CORONA/COVID-19- Vaccines Current Scenario

Authors

  • Pallavi Pogaku  Assistant Professor, Department of Microbiology, Government Degree & PG College, Siddipet (A) , Telangana, India
  • G Renuka  Assistant Professor, Department of Microbiology, Government Pingle Degree & PG College for Women, Warangal, Telangana, India
  • S Ram Reddy  Department of Microbiology, Kakatiya University, Warangal, Telangana, India

Keywords:

Corona virus, SARSCoV-2, COID-19, Vaccines, Vaccine platforms, Covaxin, Covishield

Abstract

The pandemic COVID -19 caused by novel coronavirus, SARSCoV-2, has infected more than 125 million individuals and resulted in over 2,756,768 deaths globally spread over 219 countries and territories. There has been an intensive search for an effective drug against the virus and the resultant disease. However, till now no single effective drug could be found against SARS-CoV-2. Hence, all research efforts to contain the epidemic are being focussed on effective vaccine development. Here, we review the current scenario of vaccines being developed all over the world and also India to restrict the COVID-19. Advances in genetic sequencing and other technological developments have speeded up the establishment of a variety of vaccine platforms. Most of the platforms mainly based upon the viral spike protein due to its vital role in viral infectivity. Accordingly, numerous vaccines are under various stages of development. Some vaccines like Astra-Geneca, Moderna, Covaxine, and Pfizer are already released for vaccination to general public. Principles, advantages and disadvantages of different vaccine platforms are discussed. Notwithstanding the tall claims made by manufacturers, concerns are expressed especially over the rush, at which the vaccines are developed, and their efficacy and safety. In India, two vaccines viz, covaxin and covishield are released even before finishing the mandatory phase III trials on conditional trial basis. Salient features and differences between these two vaccines are discussed.

References

  1. Calina et al.,: Towards effective COVID‑19 vaccines: Updates, perspectives and challenges (Review) International Journal of Molecular Medicine 46: 3-16, 2020
  2. Cohen J. Vaccine wagers on coronavirus surface protein pay off. Science. 2020; 370:894–5.
  3. Corey L, Mascola JR, Fauci AS, Collins FS. A strategic approach to COVID-19 vaccine R&D. Science. (2020) 368:948–50. doi: 10.1126/science.abc5312
  4. Covaxin-Fact sheet for SARS-CoV-2 vaccine issued by Bharat Biotech Ltd, Hyderabad
  5. Covishield-Fact sheet for in prevention of (covid-19) disease issued by Serum Institute of India, Pune
  6. Deming ME, Michael NL, Robb M, Cohen MS, Neuzil KM. Accelerating development of SARS-CoV-2 vaccines - the role for controlled human infection models. N Engl J Med. (2020) 383:e63. doi: 10.1056/NEJMp20 20076
  7. DeStefano F, Bodenstab HM and Offit PA: Principal controversies in vaccine safety in the United States. Clin Infect Dis 69: 726‑731, 2019.
  8. Folegatti PM, Ewer KJ, Aley PK, Angus B, Becker S, Belij-Rammerstorfer S, et al., Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomized control trial. Lancet. (2020) 396:467–78. doi: 10.1016/S0140-6736(20)31604-4
  9. Food & Drug Administration. Beware of fraudolent coronavirus tests, vaccines and treatments. 2020. https://www.fda. gov/consumers/consumer-updates/beware-fraudolent-coronavirustests- vaccines-and-treatments.
  10. Forni G, Mantovani A, Moretta L, Rezza G Vaccines. Accademia Nazionale dei Lincei. 2018. https://www.lincei.it/it/article/i-vaccini-vaccines-position-paper.
  11. Garber K. Coronavirus Vaccine Developers Wary of Errant Antibodies. (2020). Available online at: http://www.nature.com/articles/d41587-020-00016-w (accessed August 20, 2020).
  12. Global Vaccine Summit (2020). Available online at: https://www. gavi.org/investing-gavi/resource-mobilisation-process/gavis-3rd-donorpledging- conference-june-2020 (accessed July 6, 2020).
  13. Global Vaccine Summit 2020. (2020). Available online at: https://www. gavi.org/investing-gavi/resource-mobilisation- rocess/gavis-3rd-donorpledging- conference-june-2020 (accessed July 6, 2020).
  14. Han S: Clinical vaccine development. Clin Exp Vaccine Res 4: 46‑53, 2015.
  15. Krammer F. SARS-CoV-2 vaccines in development. Nature. 2020;586:516–27.
  16. Makhoul M, Ayoub HH, Chemaitelly H, Seedat S, Mumtaz GR, Al-Omari S, et al., . Epidemiological impact of SARS-CoV-2 vaccination: mathematical modeling analyses. medRxiv [Preprint]. (2020). doi: 10.1101/2020.04.19.20070805
  17. Morris KV. The improbability of the rapid development of a vaccine for SARS-CoV- .Mol Ther. (2020) 28:1548–49. doi: 10.1016/j.ymthe.2020.06.005
  18. Pollard AJ. Notice of addendum to article reporting Oxford trial of ChAdOx1nCoV-19 vaccine. Lancet. 2020;396:e89.
  19. Pronker ES, Weenen TC, Commandeur H, Claassen EH and Osterhaus AD: Risk in vaccine research and development quantified. PLoS One 8: e57755, 2013.
  20. Sharma O, Sultan AA, Ding H and Triggle CR (2020) A Review of the Progress and Challenges of Developing a Vaccine for COVID-19. Front. Immunol. 11:585354. doi: 10.3389/fimmu.2020.585354
  21. Span P. Older Adults May Be Left Out Of Some COVID-19 Trials. (2020). Available online at: https://www.nytimes.com/2020/06/19/health/vaccinetrials- elderly.html (accessed July 6, 2020).
  22. Sumner M. Why One Vaccine is Already a Sure Loser, and also a Sure Winner, in the Race to Inoculate the World. (2020). Available online at: https://www. dailykos.com/stories/2020/7/24/1963291/-Why-one-vaccine-is-alreadya- sure-loser-and-also-a-sure-winner-in-the-race-to-inoculate-the-world (accessed July 27, 2020).
  23. Wadman M. Vaccine opponents are gaining in Facebook ‘battle for hearts and minds,’ new map shows. Science. 2020. https://doi. org/10.1126/science.abc7822.
  24. WHO. Draft landscape of COVID-19 candidate vaccines. 2020. COVID-19-candidate-vaccines. Akst J. COVID-19 vaccine frontrunners. The Scientist. 2020. https://www.the-scientist.com/news-opinion/covid-19-vaccinefrontrunners- 67382.
  25. Woff T, O'Neil RE, Palese P. J Virol. 1998;72:7170–7180
  26. Zhu FC, Guan XH, Li YH, Huang JY, Jiang T, Hou LH, et al., . Immunogenicity and safety of a recombinant adenovirus type-5-vectored COVID-19 vaccine in healthy adults aged 18 years or older: a randomized, double-blind, placebo-controlled, phase 2 trial. Lancet. (2020) 396:479– 88. doi: 10.1016/S0140-6736(20)31605-6

International Journal of Scientific Research in Science and Technology

Downloads

Published

2021-04-30

Issue

Volume 8, Issue 2, March-April-2021

Section

Research Articles

License

Copyright (c) IJSRST

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

How to Cite

[1]
Pallavi Pogaku, G Renuka, S Ram Reddy "CORONA/COVID-19- Vaccines Current Scenario" International Journal of Scientific Research in Science and Technology(IJSRST), Online ISSN : 2395-602X, Print ISSN : 2395-6011,Volume 8, Issue 2, pp.352-368, March-April-2021.